Biotech entity
Every one of those 2 sits in a single category, fda-approval. FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 7.5, the average consequence score sits above the same-window beat average of 6.3.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, fda-approval. FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 7.5, the average consequence score sits above the same-window beat average of 6.3. They are less corroborated than the beat average, carrying 4 original sources each against 4.2 for the same window. We currently track 2 Biotech stories that mention mRNA-1010, published between February 18, 2026 and February 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 40 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering mRNA-1010. Shared-story counts are live from our verified record — not editorial picks.
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Source: baltimoresun.com · beckershospitalreview.com
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
Source: toronto.citynews.ca · bostonglobe.com
mRNA-1010 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
